SI-BONE, Inc. (SIBN) is a leading medical device company known for pioneering the field of minimally invasive sacroiliac (SI) joint treatment. Founded in 2008, the company is headquartered in Santa Clara, California, with additional offices across the United States and internationally. The company is publicly traded on the NASDAQ under the symbol "SIBN".
The company is primarily focused on the development of innovative and proprietary treatment methods for patients suffering from the debilitating effects of SI Joint disorders. The sacroiliac joint is often a significant source of lower back pain and its diagnosis and treatment have historically been problematic due to the complex nature of the joint and surrounding anatomy. SI-BONE, Inc. addresses this issue by delivering cutting-edge technology and dedicated procedural solutions.
The company's flagship product is the iFuse Implant System®. It is a minimally invasive surgical (MIS) solution that uses a small series of triangular, titanium implants to stabilize and fuse the sacroiliac joint. This differs from the traditional open surgical sacroiliac joint fusion methods that involve significant bone removal and large, less anatomically fitting implants. Since its inception, the iFuse Implant System® has been used in over 45,000 procedures and is backed by a large amount of published clinical evidence demonstrating its effectiveness and safety.
In 2020, SI-BONE, Inc. introduced iFuse Bedrock™, an innovative technology to treat adult patients with degenerative sacroiliitis and sacroiliac joint disruptions. This has further boosted the company’s ability to meet the unfulfilled needs of patients suffering from sacroiliac joint disorders.
Corporate responsibility is also a key pillar in SI-BONE, Inc.’s operations. The company is committed to upholding high ethical standards in its business practices and strives to make a positive impact on society through an emphasis on patient safety, environmental sustainability, and robust corporate governance structures.
Since its foundation, SI-BONE, Inc. has positioned itself at the forefront of the spine industry. The company has continued to innovate and improve treatments for sacroiliac joint disorders, significantly improving the quality of life for thousands of patients worldwide. SI-BONE, Inc. remains committed to maintaining the highest standards of patient care, research, and product innovation.